Antihypertensive agents and the risk of new onset diabetes mellitus;Antihipertenzivni lijekovi i rizik od novonastale šećerne bolesti

Lijecnicki Vjesnik

Volumn 128, Issue 11-12, 2006, Pages 336-341

  Kuzmanić, Duško ^a   Laganović, Mario ^a   Dika, Živka ^a   Kos, Jelena ^a   Pećin, Ivan ^a  

^a KBC Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NATEGLINIDE; NEBIVOLOL; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ARTICLE; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG MECHANISM; ETHNIC GROUP; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PATIENT MONITORING; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPERTENSION; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 33845625615     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Diabetes. International Diabetes Federation. Retrieved 29 august 2005 from http://www.catlas.idf.org.
2. Zavaroni I, Mazza S, Dall'Aglio E i sur. Prevalence of hyperinsulinemia in patients with high blood pressure. J Intern Med 1992;231:235-40.
3. Sowers JR. Insulin resistance and hypertension. Am J Physiol 2004; 286:H1597-602.
4. Ford ES, Abbasi F, Reaven GM. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 2005;181:143-8.
5. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care 2002;25:1-8.
6. D'Agostino RB Jr, Hamman RF, Karter AJ i sur. Cardiovascular disease risk factors predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004;27:2234-40.
7. Cranston WI, Juel-Jensen BE, Semmence AM i sur. Effects of oral diuretics on raised arterial pressure. Lancet 1963;186:966-70.
8. Medical Research Council. Adverse reactins to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 1981;2: 543-9.
9. Pfeffer MA, Swedberg K, Granger CB i sur. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM - Overall programme, Lancet 2003;362:759-76.
10. Yusuf S, Sleight P, Pogue J i sur. Effect of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
11. Braunwald E, Domanski MJ, Fowler SE i sur. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
12. Lithell H, Hansson L, Skoog I i sur. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
13. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
14. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
15. Lindholm LH, Persson M, Alaupovic P i sur. Metabolic outcome during 1 year in newly detected hypertensive: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21:1563-74.
16. Hansson L, Lindholm LH, Niskanen L i sur. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999;353:611-6.
17. Dahlof B, Devereux RB, Kjeldsen SE i sur. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
18. Hansson L, Lindholm LH, Ekborn T i sur. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension - 2 study. Lancet 1999;354:1751-6.
19. Wing LM, Reid CM, Ryan P i sur. A comparison of outcomes with angiotensin converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
20. Brown MJ, Palmer CR, Castaigne A i sur. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.
21. Pepine CJ, Handberg EM, Cooper-DeHoff RM i sur. A calcium antagnoist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil - Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.
22. Hansson L, Hedner T, Lund-Johansen P i sur. Randomised trial of effect of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.
23. Dahlof B, Sever P, Poulter NR i sur. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT - BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
24. Julius S, Kjeldsen SE, Weber M i sur. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
25. Aksnes TA, Kjeldsen SE, Mancia G. The effect of antihypertensive agents on new-onset diabetes mellitus. Am J Cardiovasc Drugs 2006; 6:139-1.
26. Gerstein HC, Yusuf S, Holman R i sur. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetol 2004;47:1519-27.
27. Teo K, Yusuf S, Sleight P i sur. Rationale, design and baseline characteristics of 2 large simple, randomized trials evaluating telmisartan, ramipril and their combination in high risk patients (ONTARGET/TRANSCEND trials). Am Heart J 2004;148:52-61.
28. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006;29:1065-70.
29. Pollare T, Lithell H, Berne C. A comparison of the effect of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-73.
30. Stump CS, Hamilton MT, Sowers JR. Effect of antihypretensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 2006; 81:796-806.
31. Mancia G, Grossi G, Zanchetti A. New onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3-10.
32. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. Q J Med 2006;99:431-6.
33. Jandeleid-Dahm KAM, Tikelis C, Reid CM i sur. Why blockade of the RAS reduces the incidence of new-onset diabetes. J Hypertens 2005; 23:463-73.
34. Sharma AM, Janke J, Gorzelniak K i sur. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40:609-11.
35. Benson SC, Peshadsingh HA, Ho CI i sur. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma modulating activity. Hypertension 2004;43:993-1002.
36. Dunder K, Lind L, Zethelius B i sur. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort. Br Med J 2003;326:681.
37. Verdecchia P, Reboldi G, Angeli F i sur. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9.
38. Bakris GL, Molitch M, Sowers JR i sur. Differences in glucose tolerance between antihypertensive combination drugs in metabolic syndrome patients. Results of the study of trandolapril/verapamil SR and insulin resistance (STAR). Diabetes care (u tisku).